FDA Concern Over Serevent, Advair & Foradil (Take 2)

When I write about asthma, I often assume (wrongly) that you’ve been dealing with the disease for 8 long years, same as me. I also sometimes leave out information in the interests of space and time and the desire not to repeat what you already know. However, my blog stats reveal searches for info about pediatric use of meds like Serevent, and in the wake of a new FDA review, who isn’t concerned? Here’s more about Serevent, Advair, and Foradil and the FDA’s concern about children using them. If you already know what I’m talking about, just ignore this post for something more interesting.

1. Serevent, Advair, and Foradil are long-acting beta 2-agonists (LABA’s), meaning they relax smooth muscles around the bronchial tubes to open airways the way albuterol does, only they do it over the long term to help control asthma. Albuterol, on the other hand, takes around 5 to 20 minutes for immediate relief.

2. That means LABA’s will not stop an asthma flare. Although they are bronchodilators, they are maintenance inhalers rather than quick-relief ones.

3. Serevent, Advair, and Foradil are approved for children over the age of 4 and adults, but are only prescribed for moderate to severe asthma that will not respond to inhaled corticosteroids alone. Doctors consider them an *add-on* treatment and like inhaled corticosteroids best for preventation.

4. The recent study that has the FDA concerned about asthma-related deaths in children was for salmeterol, the active ingredient in Serevent and one of 2 active ingredients in Advair. Foradil uses formoterol, which was not studied. The FDA wants a further review of pediatric use of all 3.

For more information, check out these places:

More About the FDA Decision (scroll to the end)
Mayo Clinic Asthma Medications List
Advair Prescribing Information (pdf)
Serevent Prescribing Information (pdf)
Foradil Prescribing Information (pdf)